Drug Search Results
More Filters [+]

SAR407899

Alternative Names: sar407899
Latest Update: 2019-02-07
Latest Update Note: News Article

Product Description

Mechanisms of Action: ROCK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SAR407899

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Coronary Artery Disease|Angina, Stable|Microvascular Angina|Myocardial Ischemia|Erectile Dysfunction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACT14656

P2

Terminated

Microvascular Angina|Angina, Stable|Coronary Artery Disease|Myocardial Ischemia

2018-07-23

2016-000629-38

P2

Completed

Coronary Artery Disease

2018-07-23

RHOKET

P2

Completed

Erectile Dysfunction

2009-09-01

Recent News Events

Date

Type

Title

02/07/2019

News Article

Sanofi delivers 2018 business EPS growth of 5.1% at CER